In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030. The burgeoning demand in…

Gene editing company Precision BioSciences (Nasdaq:DTIL) has announced that preclinical research involving in vivo gene editing targeting hepatitis B virus (HBV) has been published in Molecular Therapy. In the research, the company used an engineered ARCUS nuclease (ARCUS-POL) targeting the Hepatitis B virus (HBV) genome. In this preclinical study, ARCUS efficiently targeted and degraded HBV covalently…